Bristol Myers Squibb

News

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

The House China Select Committee has quizzed MSD, AbbVie, Bristol Myers Squibb, and Pfizer about the ethics of clinical trials run in China.

News

New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.

News

The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.

News

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.